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ABSTRACT
Though differentiated thyroid carcinomas have decent prognosis when detected early,
radioactive iodine (RAI) resistant and advanced thyroid cancers are still difficult to treat with
existing therapies. Better therapeutic agents are needed. Studies have shown that aggressive
thyroid cancers (ML-1) express the extracellular matrix protein, matrix metalloproteinase
(MMP-2). MMP-2 has been linked to metastasis and aggressiveness of several cancers and has
been shown to play a crucial role in tumor invasion. Chlorotoxin is a selective MMP-2 receptor
agonist, and Saporin is a well-known ribosome-inactivating protein used for anti-cancer
treatment; however, these two agents have never been studied when conjugated together. I
hypothesize that Chlorotoxin-conjugated to Saporin (CTX-SAP) would impede the growth of
aggressive thyroid cancer cell lines expressing MMP-2 receptors. Moreover, there is also an
unmet need for better platinum-based anti-cancer drugs. Cisplatin, an FDA approved anti-cancer
drug was tested alongside the novel cyanoximate, Pt (DECO)2 for its ability to reduce cell
viability, reduce superoxide, and increase apoptosis. Results from my study support the potential
of CTX-SAP, but offer limited availability for future study. My findings also demonstrate that
Pt (DECO)2 is more effective at reducing cell viability, reactive oxygen species, and increasing
apoptosis compared to Cisplatin.
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INTRODUCTION

Cancer
Cancer poses a threat to human life worldwide, and no one person is exempt from its
terrible effects. It is the second leading cause of death in the United States; with recent
advancements in medicine, it still takes millions of lives annually (Siegel, Miller et al., 2019).
Cancer is characterized as over 100 different types of diseases that can be depicted by
uncontrolled cell growth or invasion. These cells originate from healthy cells found in the body
that have undergone a genetic transformation that leads to uncontrolled proliferation, and
eventually tumor growth (Fouad and Aanei, 2017). These tumors are what we envision when
thinking about cancer symptoms and disease progression.

Thyroid Cancer
Thyroid cancer is the most common endocrine malignancy worldwide and has seen
growing incidence over the last decade (Grimm, 2017; Rahib, Smith et al., 2014). Estimated
incidence of thyroid cancer in the United States for 2020 is 52,890 (Morris, Sikora et al., 2013).
It is predicted that by the year 2030, thyroid cancer will be the fourth leading cause of new
cancer diagnoses in the United States, replacing that of colorectal cancer (Rahib, Smith et al.,
2014). According to the American Thyroid Association, an estimated 20 million Americans have
some form of thyroid disease, and of that population, 60% are unaware of their condition
(American Thyroid Association, https://www.thyroid.org/media-main/press-room/).The
American Cancer Society distinguishes four different types of thyroid cancers (Table 1), with
two distinct epithelial-cell origins. Papillary Thyroid Cancers (PTC), Follicular Thyroid Cancers
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(FTC), and Anaplastic Thyroid Cancers (ATC) are all derived from the follicular cells found in
the thyroid epithelium, whereas Medullary Thyroid Cancers (MTC) are derived from the
parafollicular or C-cells. Papillary thyroid cancers account for about 80% of all thyroid cancers,
making them the most abundant form of thyroid cancer, while also being the least aggressive
type. Follicular thyroid cancers account for about 20% of thyroid cancers, and Anaplastic thyroid
cancers account for about 2% of all thyroid cancers and tend to be the rarest form of thyroid
cancer. Lastly, Medullary thyroid cancers account for about 4% of all thyroid cancers and can
also be familial. The remaining ~4% of thyroid cancer cases are due to Hurthle cell thyroid
cancers or other rare forms of thyroid cancer. Most thyroid cancers respond well to surgical
resection, radioactive iodine, thyroid stimulating hormone (TSH) suppression, tyrosine kinase
inhibitors, or external beam radiation (Table 2). However, a subset of these thyroid cancers will
develop metastasis and become resistant to radioactive iodine (RAI) treatment (Hirshfield,
Aisner et al., 2017), or incur a genetic mutation (Cohen and Lippard, 2001), making them harder
to remove. Even with newer therapeutic agents like tyrosine kinase inhibitors, it is very difficult
to prevent progression of RAI-resistant metastatic thyroid cancer. Despite advancements in
diagnosis and treatment, there is an unmet need for better therapeutic agents in this scenario for
the treatment of thyroid cancer, and more specifically for the treatment of RAI-resistant, or dedifferentiated thyroid cancers.

Cell line
ML-1 (ACC-464), thyroid cancer cell line is derived from a dedifferentiated recurrent
follicular thyroid carcinoma from a 50-year-old patient. ML-1 is tumorigenic in rodents and has
been found to express matrix metalloproteinase-2 (MMP-2), which are extracellular matrix
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proteins associated with remodeling and growth factor signaling in healthy cells (Noel,
Gutierrez-Fernandez et al., 2012). MMP genes also display a high conservation in regards to
their modular structure, and have also been known to play a crucial role in tumor invasion of
several cancers (Chakraborti, Mandal et al., 2003). In many cancers, including thyroid, it has
been found that MMP-2 is upregulated by the cancer cells; therefore, MMP-2 makes for an ideal
protein for target-specific therapy (Grosse, Warnke et al., 2013; Cho Mar, Eimoto et al., 2006).

Current Therapy for Thyroid Cancer
Treatment options for thyroid cancer vary depending on the type of cancer (histology),
disease stage and patient characteristics as seen in Table 2. At present, traditional therapies
include the use of surgery (thyroidectomy), radioactive iodine, targeted therapies such as tyrosine
kinase inhibitors or chemotherapeutic drugs, and external beam radiation. For those individuals
that do not wish to completely remove their thyroid, or for cancer in a less progressed state, they
can opt for a partial removal of their thyroid, known as a thyroid lobectomy (Sephton, 2019).
Additionally, when surgical intervention is required, removal of the lymph nodes in the neck can
be necessary to test for cancerous cells as well.
Radioactive iodine treatment, alongside surgical resection or combination therapies has
proven to be the most effective solution to treat thyroid cancer. The purpose of RAI therapy is to
completely obliterate any remaining thyroid tissue in the body. However, there are still thyroid
cancers that no longer uptake iodine (RAI resistant/refractory) and do not respond to RAI, so
there is a need for other, better-targeted treatments for these thyroid cancers.
For cancers resistant to RAI therapy, external beam radiation, chemotherapy, and tyrosine
kinase inhibitors are typically the alternatives for treatment. The use of targeted systematic
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therapies represents major advances for patients with RAI-resistant differentiated thyroid
cancers, that until recently, had only few treatment options (Worden, 2014). Currently, the Mayo
Clinic and the American Cancer Society recommend clinical trials for patients with advanced
RAI-resistant thyroid cancer (https://www.cancer.org/cancer/thyroid-cancer/treating/bystage.html) leading to the need for development of other potential chemical agents that can be
used for treatment.

Alternative Chemotherapeutic Drugs
Chlorotoxin (CTX) is a 36-amino acid peptide derived from the venom of the death
stalker scorpion, Leiurus quinquestriatus (Dardevet, Rani et al., 2015). It was originally used as a
pharmacologic tool in studying chloride channels in glioma-specific currents but has gained
popularity in cancer research upon the discovery that it possesses targeting properties in many
different cancers (Dardevet, Rani et al., 2015). Specifically, it has been shown to bind selectively
to isoform 2 of matrix metalloproteinase (MMP-2) (Deshane, Garner et al., 2003). MMP-2 is
overexpressed in aggressive thyroid cancers when compared to normal thyroid tissue (Cho Mar,
Eimoto et al., 2006). Aggressive follicular thyroid cancers, like ML-1, were also found to
overexpress MMP-2 (Cho Mar, Eimoto et al., 2006).
Saporin (SAP), also known as Saporin-S6, is a 30 kDa protein derived from a class of
ribosome inactivating proteins originating from the seeds of the Soapwort plant Saponaria
officinalis (Polito, Bortolotti et al., 2013). The mechanism of action for Saporin has been well
studied and has been successfully employed in the creation of many immunotoxins. Like most
ribosome-inactivating proteins, Saporin contains enzymes that depurinate rRNAs resulting in the
inhibition of protein synthesis (Polito, Bortolotti et al., 2013; Stirpe and Battelli, 2006). Saporin
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makes for a great candidate in immunological studies as it is very stable in vivo and is resistant to
proteases in the blood (Polito, Bortolotti et al., 2013). Since Saporin works through many
different cell death pathways, it is hard to develop resistance to it (Polito, Bortolotti et al., 2013).
Saporin by itself is unable to cause significant cell damage, as it is not efficient in passively
entering or being endocytosed into cells. However, when conjugated with antibodies or other
toxins that promote its internalization, it confers lethality as these conjugates have apoptotic and
necrotic properties (Stirpe and Battelli, 2006). The first study using an antibody conjugated with
SAP was conducted in humans for refractory Hodgkin’s disease (Falini, Bolognesi et al., 1992).
Seventy-five percent of the patients achieved complete remission and fifty percent experienced
relief from symptoms (Falini, Bolognesi et al., 1992). A recent study used Substance P
conjugated with Saporin intrathecally in cancer patients with intractable pain to confirm that
Saporin can safely and effectively be used at low doses (Frankel, Nymeyer et al., 2014).
Cisplatin (cis-diamminedichloroplatinum, DDP) is a square planar compound with a
molecular weight of 300.1 g/mol, and is among the most effective and widely used
chemotherapeutic agents for treatment of solid tumors today. In 1978, it became the first FDAapproved platinum compound for cancer treatment (Dasari and Tchounwou, 2014). It is an
effective inducer of apoptosis and cell cycle arrest in most cancer cell types as it forms inter- and
intra-strand adducts with DNA, and leads to crosslinking of purine bases (Cohen and Lippard,
2001). Its effects have been studied in lung, ovarian, testicular, and head and neck cancers.
However, cancer cells can develop resistance to Cisplatin over time, which leads to the rationale
behind studying alternative platinum-based chemical agents. This resistance is typically
attributed to: 1) reduced intracellular cisplatin accumulation due to poor drug transport or
endocytosis; 2) an elevated drug detox system attributed to increased levels of intracellular
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proteins like metallothioneins or glutathione; 3) alteration in DNA repair mechanisms that
include enforced base excision repair or mismatch repair systems; 4) changes in DNA damage
tolerance; and 5) changes in the cancer cells apoptotic cell death pathways or cell cycle arrests
(Dasari and Tchounwou, 2014).

Platinum-Derived Pt (DECO)2 and Pd (DECO)2
Platinum 2-cyano-2-oximino-N,N′-diethylaminoacetamide, or Pt (DECO)2 and Palladium
2-cyano-2-oximino-N,N′-diethylaminoacetamide, or Pd (DECO)2 are platinum-derived
cyanoximates. A cyanoxime is simply a biologically active organic molecule that binds to metal
ions via nitrosation reactions. They work as excellent ligands and also as carbonyl reductase
inhibitors. They have since been understudied as an alternative to pre-existing metal-containing
chemotherapy anti-cancer drugs, such as Cisplatin. Platinum containing anti-cancer drugs are
prescribed regularly for treatment of cancer patients. Even though they are very effective, their
use is limited due to their high toxicity, poor water solubility, and other several adverse effects
associated with heavy-metal drugs, such as organ failure or metal toxicity in human systems
(Oun, Moussa et al., 2018; Eddings, Barnes et al., 2004). Nevertheless, there is still a great need
for further research in different metal-based anti-cancer drugs as tumors consistently develop
drug tolerance over time.

Consequences of Treatment
Like with most other diseases, treatment is never 100% without consequence or sideeffect profiles. Current consequences of undergoing thyroidectomy or thyroid lobectomy include
damage to the parathyroid, which can result in reduced levels of calcium circulating in the body
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(Chahardahmasumi, Salehidoost et al., 2019). Aside from that, surgery also runs the risk of
bleeding as well as infection, and ultimately can result in temporary to permeant nerve damage to
the vocal cords that could result in difficulty breathing and speaking (Chahardahmasumi,
Salehidoost et al., 2019). External beam radiation therapy, or EBRT, can also consequently cause
cancer development in local tissue in the future. This is due largely due to the ionizing radiation
causing damage to DNA allowing for those genetic transformations as discussed earlier.

Hypothesis
I hypothesize that with less evasive, alternative chemotherapeutic agents, such as the ones
introduced in this study, elimination of thyroid cancer may be more efficient, circumventing the
need for more invasive therapies.
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MATERIALS AND METHODS

Materials
Dulbecco’s Modified Eagle Medium (DMEM; #10-017-CV), fetal bovine serum (#35010-CV), Penicillin and Streptomycin antibiotics (# 30-002-CI), 75cm2 and 25cm2(#430639,
#430641U, respectively) culture flasks (were ordered through Corning (New York, USA).
Annexin V-APC (#A35110), Propidium Iodide (#P1304MP), Phosphate Buffered Saline
(PBS; # AM9624), Trypsin (#15050057), and Trypsin-EDTA (#25200056) were ordered through
Thermo Fisher (USA).
XTT assay and reagents were received from Biotium (Fremont, CA, #3007).
All platinum-based toxins, Cisplatin, Pt (DECO)2, Pd (DECO)2 were acquired from Dr. Nikolay
Gerasimchuk in the Missouri State Chemistry Department in Springfield, Missouri.

Cell Culture
The cell line used in these studies was ML-1 (ACC-464), which was derived from a stage
4, dedifferentiated follicular thyroid carcinoma from the DSMZ German Leibniz Institute of
Microorganisms and Cell Cultures
(www.https://www.dsmz.de/collection/catalogue/details/culture/ACC-464). Cells were
authenticated by the DSMZ and Genetica DNA Laboratories (Burlington, NC) and cultured in
Gibco Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine
serum (FBS) and 1% penicillin and streptomycin antibiotics. Cultures were maintained at 37°C
and 5% CO2 in a cell-culture treated 75 cm3 corning culture flask until optimal confluency was
reached (75-85%), or stored in liquid nitrogen for long term storage. This cell line was of interest
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for this study as it has been known to express MMP-2, which made it a great candidate for
testing target-specific chemicals in the ML-1 cells, which are a well-progressed dedifferentiated
cell line. All research was approved by the Missouri State University Biosafety committee and
institutional review board (IRB) approval was not required.

Toxins
The Chlorotoxin-Saporin (Beta 010) conjugate was acquired from Advanced Targeting
Systems (San Diego, CA). This toxin consisted of biotinylated Chlorotoxin bound to a secondary
conjugate of Streptavidin-ZAP containing Saporin. Unconjugated Saporin and Chlorotoxin were
acquired through Sigma-Aldrich (St. Louis, MO) and solubilized in DMEM.

Conjugated Toxins
After allowing cells 24 hours to incubate and attach to their respective wells (10,000
cells/well on 96-well plate), 2 µM stocks of Chlorotoxin, Saporin, and Chlorotoxin-Saporin
(CTX-SAP) treatments were prepared (www.https://www.atsbio.com/catalog/data/beta010.pdf).

Platinum-Derived Toxins and Solubility Tests
It has been shown that Cisplatin, as well as Pt and Pd (DECO)2 can only be solubilized in
organic solvents such as Dimethyl Sulfoxide, or DMSO (Eddings, Barnes et al., 2004). However,
what had not yet been studied was the amount/percent of DMSO needed to solubilize these
compounds per mg of chemical agent that wouldn’t reduce viability of thyroid cancer cells
(Table 3). Therefore, a viability test was conducted as seen in Table 3 to determine what percent
of DMSO was needed to solubilize each toxin without causing toxicity starting at 100% DMSO

9

and then making lower dilutions in DMEM. Based on results from this pilot study, it was
determined that a 2% DMSO concentration in DMEM could serve as a negative control since
this concentration did not cause a significant reduction in viability in those groups (Figure 1). It
was also determined that this concentration of DMSO was sufficient to solubilize the toxins.
These tests were done by treating wells seeded with 10,000 cells/well with varying
concentrations of DMSO and performing an XTT cell viability assay.

XTT Cell Viability Assay
XTT (2,3-Bis-(2-Methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide,
disodium salt) is a colorimetric, reduction-based proliferation assay that quantifies cellular
proliferation and viability based on the cleavage of the tetrazolium salt, XTT
(https://www.atcc.org/~/media/Attachments/5/6/3/7/16747.ashx). After 24 hours of incubation
with chemical agents, 25 µL of activated XTT dye was added into each triplicate well of 7,50010,000 cells (without removing media) on the 96-well plate according to the Biotium
manufacturer’s guidelines (www.https://biotium.com/wp-content/uploads/2013/07/PI-30007.pdf)
and quantified using a multi-well spectrophotometer (BioTek ELx808) set to Delta (A450-A630)
using a Gen5 plate reading software (number of experimental replicates, n=3). Absorbance at
hours 0-7 with XTT dye was recorded and quantified to determine the levels of reduction in
viable cells (Aslantürk, 2017).

Native Gel
To test if Chlorotoxin and Saporin were successfully conjugated together, the sample was
loaded on a non-denaturing native polyacrylamide gel and band patterns were compared with a
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standard ladder (BIO-RAD, USA). If samples were unconjugated, an 85 kDa protein band of
SAP-Strep would be visible, and a 5 kDa band would be expected for Biotinylated CTX.
Samples were stained with Coomassie Blue and imaged using an Azure c300 gel imager.

Reactive Oxygen Species
In order to measure levels of superoxide production, dihydroethidium (DHE) was utilized
in this experiment (Biotium; Fremont, CA). DHE was dissolved in DMSO, and a 10 mM stock
was made. On the day of the experiment, a 10 μM working solution was made in PBS. A 24-well
plate was seeded at a density of 50,000 cells/well and incubated for 24 hours (n=3). Wells were
then treated with 1.0 mM Cisplatin and Pt (DECO)2 in 2% DMSO for 24 hours. After harvesting
cells in each well, pellets were resuspended in 1 mL of the 10 μM DHE working solution and
incubated for 30 minutes in the dark. After incubation, cells were analyzed with an Attune NxT
flow cytometer (ThermoFisher, USA). Excitation and emission wavelengths of DHE were 518nm
and 606nm, respectively.

Programmed Cell Death Measurements
Programmed cell death, or apoptosis, was measured using an Attune NxT flow cytometer
(ThermoFisher, USA) following the manufacturer’s protocol. Using a 24-well plate, 50,000
cells/well were seeded and incubated for 24 hours on a 24-well plate (n=3). After incubation,
wells were treated with 1.0 mM concentrations of Cisplatin or Pt (DECO)2 for 24 hours. After
incubation, wells were harvested and resuspend with 1X Annexin V binding buffer
(www.http://cshprotocols.cshlp.org/content/2016/11/pdb.rec088443.short) containing Annexin
V-APC and propidium iodide based on manufacturer’s guidelines (BD Biosciences, USA). Cells
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were incubated with these dyes for 15 minutes and analyzed with flow cytometry. Annexin VAPC has an excitation wavelength of 650 nm and PI has an excitation wavelength of 617 nm.

Statistical Analysis
Prism8 statistical software (GraphPad Software Inc.) was used to conduct statistical
analyses. One-Way ANOVA was performed assuming Gaussian distribution to compare
absorbance values between toxin-treated groups and non-treated controls. Post hoc comparisons
were done running Dunnett’s test to compare values from toxin-treated groups to the non-treated
control (NTC). All values are expressed as the mean and standard deviation of recorded values in
triplicate. N refers to the number of plates included in each experiment. P-values calculated from
Dunnett’s test were adjusted to account for multiple comparisons.
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RESULTS

Cancer Cell Viability Tests
To assess if a dose-dependent reduction of cell viability was present, ML-1 cells were
treated with conjugated Chlorotoxin-Saporin at concentrations ranging from 0 to 200 nM for 72
hours (Figure 2A). There was an overall statistically significant difference in cell viability at 7
hours of incubation with XTT and PMS after 7 hours of treatment (F=4.286, p=0.0057) with an
apparent dose-dependent trend for decreased cell viability with increasing concentration of the
conjugate. Post hoc statistical comparisons using Dunnett’s test showed no significantly reduced
viability for cells exposed to 2, 10, or 20 nM relative to non-treated control (p>0.05). However,
cells exposed to CTX-SAP conjugate at concentrations of 40, 100, and 200 nM had significantly
reduced viability relative to non-treated controls (Dunnett’s tests, p=0.0138, p=0.0052, and
p=0.0037 for 40, 100 and 200 nM, respectively, relative to non-treated control (NTC).
I repeated the experiment with a higher concentration of the CTX-SAP conjugate and
once again assessed viability at 7 hours of XTT incubation (Figure 2B). I used concentrations of
2, 20, and 600 nM, and there was a statistically significant difference in cell viability assessed
with a one-way ANOVA (F=44.24, p<0.0001). Post hoc comparisons using Dunnett’s test
revealed that viability was significantly reduced for the 600 nM group relative to the non-treated
control (difference in absorbance of 0.8410, p<0.0001). However, the lower concentrations of
the conjugate did not significantly differ from the non-treated control (p=0.2492 and p=0.5658
for 2 and 20 nM, respectively).
To determine if unconjugated Chlorotoxin exhibits cytotoxicity without Saporin, ML-1
cancer cells were treated with unconjugated Chlorotoxin at concentrations that ranged from 0 to
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600 nM for 72 hours. In Figure 2C, after 72 hours of chemical treatment, there was not an overall
statistically significant difference in cell viability assessed after 7 hours of incubation in the
presence of XTT and PMS (p>0.05). The largest difference was slightly increased viability of the
cells exposed to 600 nM of unconjugated CTX relative to the non-treated control (mean
difference in absorbance -0.054). However, this was not statistically significant with a Dunnett’s
test (p=0.1279).
To establish if unconjugated Saporin exhibits cytotoxicity without Chlorotoxin, ML-1
cancer cells were exposed to unconjugated Saporin at concentrations that ranged from 0 to 600
nM (Figure 2D). There was not an overall statistically significant difference in cell viability after
7 hours of incubation with XTT and PMS (p>0.05). The largest difference was improved
viability (absorbance) of the cells exposed to 20 nM of unconjugated SAP relative to the nontreated control (mean difference in absorbance -0.05325). However, this was not statistically
significant with a Dunnett’s test (p=0.0874).
In these novel experiments, ML-1 cancer cells were exposed to either cisplatin or the
novel cyanoximate, Pt (DECO)2, at concentrations ranging from 0 to 1.0 mM for 24 hours
(Figure 3) to assess if Pt (DECO)2 exhibits cytotoxicity similar the level observed with Cisplatin.
There was an overall statistically significant reduction in cell viability after 7 hours of incubation
of activated XTT dye (F=45.77), p<0.0001). There was an apparent dose-dependent reduction in
cell viability with increasing concentration of Cisplatin. Post hoc statistical comparisons using
Dunnett’s test showed significant reduction at 1.0 and 0.1 mM of cisplatin treatment compared to
the non-treated control (Dunnett’s tests, p<0.0001, and p=0.001, receptively). Statistical
comparisons of 1.0 mM of Pt (DECO)2 with non-treated control showed a significant reduction
in cell viability greater than what was seen by cisplatin at the same concentration (P<0.0001).
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However, at lesser concentrations of Pt (DECO)2, no significant reduction of cell viability was
observed (0.1 mM, p=0.9999; 0.01 mM, p=0.9994). Both chemicals were dissolved in 2%
DMSO, which displayed no significant reduction in cell viability when compared with the nontreated control (p=0.4376).

Native Gel
To test for successful conjugation of Chlorotoxin-Saporin, protein samples were resolved
by a non-denaturing native gel and band patterns were observed (Figure 4). Due to the nature of
the patterns, it was evident that the two chemicals had been conjugated; however not properly.
Based on the molecular weights of the protein standards included in the ladder, it was clear that
multimeric complexes had been formed according to the molecular weights present when
compared to the ladder and the weight of each individual chemical.

Platinum-Based Reduction of Superoxide
Accumulation of superoxide levels (DHE) were measured with flow cytometry to assess
changes in oxidative stress before and after treatment. Percentages of superoxide detection
utilizing the marker DHE are shown in Figure 5. At concentrations of 1.0 mM Cisplatin and Pt
(DECO)2, it was observed that levels of superoxide are significantly reduced compared to that of
the control (F= 28.57, p=0.0001). At 1.0 mM concentrations of Cisplatin, levels of superoxide
were reduced by 51.24% when compared with the non-treated control (p=0.0006). Wells treated
with 1.0 mM Pt (DECO)2 displayed a significant reduction at 46.89% (p=0.0003). Non-treated
wells and wells treated with 2% DMSO displayed the highest percent averages of superoxide
production (76.75% and 75.27%, respectively; Dunnett’s test, p=0.9884).
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Increase of Apoptosis
Changes in apoptotic levels due to treatment are seen in Figure 6. After 24 hours of
treatment, it was evident that both 1.0 mM of Cisplatin and Pt (DECO)2 treatment increased the
levels of programmed cell death (Figures 6 B,D, F, & H), compared to non-treated control
(NTC). In regard to efficacy in causing cell death, neither treatment caused increase in necrosis
(Figure 6A & E; F=1.506, p=0.2854). However, we observed a significant increase in late
apoptosis in cells treated with 1.0 mM Cisplatin and Pt (DECO)2 (F<0.0001; p=0.0025,
p<0.0001, respectively) (Figure 6F). Moreover, there was a four-fold increase of late apoptosis
with Pt(DECO)2 observed, suggesting more efficient and quicker induction of cell death (Figure
6 B & F). There was a 250% increase in early apoptosis upon treatment with 1.0 mM Cisplatin
compared to the control (Figure 6 D & H; F=16.45, p=0.0019).
To assess specificity of Cisplatin and Pt (DECO)2 on non-cancerous cells, mouse-derived
fibroblasts were treated with 1.0 mM Cisplatin or Pt (DECO)2 for 24 hours to assess changes, if
any, to cell death. Results shown in Figure 7 demonstrate that both drugs kill cells present with
no indication of specificity to killing cancer cells over non-cancer cells. An observed increase in
late apoptosis and early apoptosis was seen, with no increase in necrosis (Figure 7A & E). The
significant increase in late apoptosis due to Pt (DECO)2 treatment suggests swifter cell death
(Figure 7 B & F; F= 378.9, P<0.0001) to the cells. Additionally, viability was reduced
significantly in both treatment groups (F=130.5, P<0.0001).
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DISCUSSION

Effectiveness of CTX-SAP
The first part of my research addressed the effectiveness of the potential
chemotherapeutic benefit of a novel chemical conjugate. Biotinylated Chlorotoxin bonded to the
secondary conjugate Streptavidin-ZAP containing Saporin holds promise of being used as an
alternative chemotherapeutic agent. Results suggest that the conjugate effectively inhibited
proliferation or viability of the ML-1 thyroid cancer cells in a dose-dependent manner in vitro
(Figure 2C and 2D). Saporin, a plant toxin derived from the seed of Saponaria officinalis, aided
as an effective ribosome-inactivating protein to inhibit protein synthesis of the cancer cells in the
present study and in similar studies (Giansanti, Flavell et al., 2018; Bergamaschi, Perfetti et al.,
1996). Moreover, Chlorotoxin, a 36 amino-acid peptide from the venom of the deathstalker
scorpion, Leiurus quinquestriatus, has proven an effective vehicle for anti-cancer drug delivery
(Ojeda, Wang et al., 2016). However, my data provides evidence that the two agents need to be
bound together in order to confer any cytotoxic effect. Results shown in Figure 2A and 1B
demonstrate a lack of reduction of cancer cell viability upon unconjugated treatment. These
results are in agreement with previous reports that Saporin needs a vehicle to properly confer
lethality (Polito, Bortolotti et al., 2013). Fortunately, Chlorotoxin is a well-studied matrix
metalloproteinase isoform 2 (MMP-2) agonist, making it an effective vehicle for internalization
(Deshane, Garner et al., 2003). MMPs are extracellular matrix proteins associated with
remodeling and growth factor signaling within the cell (Deshane, Garner et al., 2003; Itoh,
Tanioka et al., 1998). MMPs are known to be upregulated in many cancers as they are implicated
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in tumor growth, angiogenesis, invasion, and inflammation (Itoh, Tanioka et al., 1998).
Activation of MMP-2 can occur at the cell membrane and is enhanced in many different cancers,
including thyroid cancers (Nakamura, Ueno et al., 1999; Aust, Hofman et al., 1997; Hofmann,
Laue et al., 1998; Han, Dugas-Ford et al., 2015). Previous studies have shown that Chlorotoxin
promotes endocytosis of MMP-2, which is directly involved with the invasive potential in ML-1
cells (Kalhori and Törnquist, 2015).
Presently, a significant dose-dependent inhibition of ML-1 thyroid cancer cell viability is
conferred upon treated cancer cells with no apparent effect upon treatment of unconjugated drug
(Figure 2). Further research needs to be done to elucidate the exact mechanism behind
internalization of Chlorotoxin conjugates into the cell. Research findings support the notion that
internalization occurs via receptor-mediated endocytosis of MMP-2 with MMP-14 (Han, DugasFord et al., 2015). Additionally, if resources were not limited with the manufacturer, more
research needs to be done to determine the effect of conjugate treatment on oxidative stress, cell
death, and specificity in non-cancerous cell lines. In my study, conjugating BiotinylatedChlorotoxin with just Streptavidin-Saporin (excluding ZAP) did not cause a significant reduction
in viability of cancer cells treated with 1.2 µM of CTX-SAP. Based on results from the nondenaturing native gel (Figure 4 and 8), multimeric complexes formed, thus suggesting a
hinderance in receptor-mediated endocytosis, ultimately mitigating the effect of the conjugate. If
conjugated successfully, we would have expected to have seen a band present around 90 kDa
representing the binding of one biotinylated Chlorotoxin to one Streptavidin-bound Saporin. The
next step after either manufacturing of CTX-SAP Beta010 is revisited or effective conjugation of
ZAP domain is accomplished would be to conduct in vivo tests to assess efficacy in
physiological conditions on healthy and cancer-induced mice.
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Assessment of Pt (DECO)2
At the start of this study, little was known about cyanoxime solubility and sensitivity to
thyroid cancer cells. Therefore, testing needed to be conducted to assess proper solubility of
cyanoximes in DMSO (Table 3) and the concentration of DMSO (Figure 1 and Figure 9)
necessary for solubilization that didn’t confer significant cytotoxicity in vitro. This was realized
upon the first XTT assay of Cisplatin, Pt (DECO)2 and Pd (DECO)2 at concentrations ranging 01.0 mM in 10% DMSO (Figure 9). Results in Figure 9 suggested drastic effects of each treatment
group to cells; however, this did not account for the drastic cytotoxic effect due to DMSO alone.
Therefore, ML-1 cells were treated with just DMSO at varying concentrations to assess the
threshold at which DMSO did not confer significant reduction on viability (Figure 1), as well as
what concentration of DMSO necessary to fully solubilize each chemical (Table 3). Dr.
Gerasimchuk in the Eddings, Barnes et al., paper solubilized the toxins in 100 mM DMSO
aliquots and diluted them down to 1.0 mM for treatment (2004). Due to limited availability of
chemicals, Pd (DECO)2 was not able to be considered for more studies as it required a higher
concentration of DMSO than did Cisplatin or Pt (DECO)2. Therefore, a final concentration of 2%
DMSO was decided to solubilize Cisplatin and Pt (DECO)2 to create 50 mM stocks for each test.

Cyanoximate Comparisons
Platinum complexes have been widely used as anticancer agents since the accidental
discovery of cisplatin as a potent anticancer treatment in 1965 (Dasari and Tchounwou, 2014;
Bergamo and Savi, 2015). Not approved by the FDA until 1978, Cisplatin and its analogs remain
the staple treatment for combating many cancers (Dasari and Tchounwou, 2014). Cisplatin,
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Carboplatin, and Oxaliplatin share similar mechanisms of action to confer toxicities, and
therefore, also share similar side effect profiles (Ndagi, Mhlongo et al., 2017). These side effects
include weakening the immune system in patients, anemia, myelosuppression, and organ/tissue
damage that can lead to nerve damage and hearing loss (Dannen, Cornelison et al., 2020).
Moreover, cancer cells can transform to acquire a resistance to Cisplatin treatment; therefore,
there is an unmet need to develop newer platinum-based anticancer drugs (Dasari and
Tchounwou, 2014; Ndagi, Mhlongo et al., 2017). The present study addressed the effectiveness
of a novel platinum-based drug, Pt (DECO)2, on its potential use as an anti-cancer drug, and its
potential for reducing cell viability, altering oxidative stress levels, and inducing cell death. Up
to this point, little research has been done to test the efficacy of metal cyanoximates and their use
in cancer therapy. In studies by Ratcliff, Kudok-Jaworska et al. and Dannen, Cornelison et al.,
the efficacy of several different metal cyanoximates, Pt (MCO)2, Pd (MCO)2, Pt (DECO)2 and
Cisplatin on reducing cell viability was investigated (2012 and 2020, respectively). The Dannen
study tested this with a trypan blue assay, which determined that both Cisplatin and Pt (DECO)2
were able to reduce cell viability in vitro (2020, submitted). In the study, viability of cervical
cancer cells (HeLa) was reduced by nearly 60% by Pt (DECO)2 and reduced by 55% in the
positive control of Cisplatin-treated cells (Appendix A). Additionally, WiDr, a colon cancer cell
line, was treated with 1.0 mM Cisplatin or Pt (DECO)2, and 95% of colon cancer cells were
killed by Pt (DECO)2 but only 12% by Cisplatin (Appendix A). In the Ratcliff and Dannen
papers, trypan blue assay was employed to differentiate between live and dead cells as the dye
only penetrates dead cells with damage to their plasma membrane (Piccinini, Tesei et al., 2017).
The main disadvantages to this technique include subjectivity judgement of the user to
differentiate between stained or unstained cells, inconsistency among different users, the amount
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of time and labor involved with measuring samples, and the error involved with only measuring
single samples at a time (Piccinini, Tesei et al., 2017). Whereas with XTT, the tetrazolium salt is
only getting reduced by metabolically active or viable cells and quantified automatically with a
spectrophotometer. Even so, our study utilizing XTT showed similar results to the Dannen paper
in that 1.0 mM Pt (DECO)2 reduced viability more effectively (by nearly 59% in thyroid cancer
cells), than Cisplatin did (only 45% of cells were killed by 1.0 mM Cisplatin treatment). Based
on results presented in the Eddings and Dannen papers, Pt(DECO)2 ranks in third place when
compared to other platinum or palladium-based cyanoximates when treating cervical or colon
cancer cells in vitro (Table 1). However, in all three cell lines (HeLa, WiDr, and Thyroid),
Pt(DECO)2 is shown to be more effective than Cisplatin at the same concentration (Dannen,
Cornelison et al., 2020). It is thought that the oxime ligand, DECO, alongside the platinum
molecule has a more efficient structure to confer lethality than Cisplatin’s square planer model
(Ratcliff, Kudok-Jaworska et al., 2012; Dannen, Cornelison et al., 2020), or that the combination
of platinum with the oxime molecules in conjunction is more effective than platinum bound to
chloride or ammonium as seen in Cisplatin.

Reduction of ROS
I found that the platinum-based nanoparticles actually reduced the level of superoxide
formed upon treatment, similarly to what was seen in the Yusof, Akmal et al. paper that
described the use of platinum nanoparticles as an antioxidant in treating lung disease (2015).
They assessed the use of platinum-based nanoparticles as an alternative drug carrier due to their
ability to produce less of an ROS-mediated effect to the system and suggested that platinum may
reverse the oxidative imbalance by affecting the epithelial sodium channel, or ENaC. ENaC
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works by downregulating the Protein Kinase C (PKC) pathway in the lungs and showed great
promise in the treatment of lung disease (Yusof, Akmal et al., 2015). In a paper by Shibuya,
Ozawa et al., it was seen that platinum nanoparticles share similar activity to that of catalase and
superoxide dismutase, which are key endogenous antioxidant enzymes found in human systems
(2014). Moreover, in a stroke mice model done by Takamiya, Miyamoto et al. (2011) there was a
significant reduction in the production of superoxide upon platinum treatment. This is in
agreement with reduced levels of superoxide observed in my study, and offers insight as to the
mechanism behind superoxide reduction. In contrast, non-treated cancer cells display increased
oxidative stress that can lead to damage in the DNA, proteins, and lipids (Li, Jia et al., 2016).

Induced Apoptosis
Programmed cell death, or apoptosis is the body’s natural mechanism for killing cells
(Goldar, Khaniani et al., 2015). Apoptosis is carried out through pathways that utilize caspases to
signal a cell for death (Pfeffer and Singh, 2018). In cancer pathology, these apoptotic pathways
are inhibited through overexpression of anti-apoptotic proteins and under-expression of
proapoptotic proteins (Pfeffer and Singh, 2018). Due to these changes, many cancers can develop
a resistance to anticancer chemotherapies. Therefore, there is an unmet need to develop new
anticancer drugs that can activate these apoptotic pathways. In my study, it was seen that
Cisplatin and Pt (DECO)2 both caused significant amounts of apoptosis. Moreover, it is
suggested that Pt (DECO)2 was more efficient in inducing cell death as seen by the increase in
apoptosis above (Figure 6F and 7F). Additionally, it can be concluded that neither Cisplatin or Pt
(DECO)2 had much specificity in the killing of rapidly diving cells, regardless if they were
cancerous or not, as seen in Figure 7. In the Dannen, Cornelison et al. paper, healthy C57BL/6
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mice were injected intraperitoneally with 1.0 mM Cisplatin and Pt (DECO)2 to assess
cytotoxicity (2020). Their results suggest a less severe side effect profile compared to Cisplatin;
however, enhanced hepatotoxicity was not addressed, even with it being a hallmark of many
chemotherapies (Gong, Qian et al., 2015).

Limitations to in vitro Studies
Through the years, in vitro studies have helped expand our knowledge and understanding
of the mechanisms of toxicity that can happen in vivo. However, it is important to understand
that even with the great deal of benefits these studies provide, there are still several limitations to
their overall reflection of what happens in an actual human system. For example, the human
body has a complex network of organs and organ systems that behave differently and
compensate to different stimuli and stress situations that cannot be replicated in vitro with a
single cell type (Aslantürk, 2017). Even with simple assays that test metabolism of different
chemicals, such as with an XTT assay, drug metabolism will vary in an actual human system
(Aslantürk, 2017). Furthermore, even primary cultivated cells tend to differ greatly from their
corresponding cell type in an actual organism, so it’s hard to predict if outcomes are going to be
fully replicable (Aslantürk, 2017) outside of exact physiological conditions. For example,
Godoy, Hengstler et al. revealed that primary hepatocytes when isolated from their normal
microenvironment display hundreds of genes that are differentially expressed and either up or
downregulated differently than what is seen in animal models (2009).
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CONCLUSION
Incidence of thyroid cancer is on the rise with over fifty-two thousand new cancer
diagnoses in the US each year. Although much is still unknown regarding the exact cause of
thyroid cancer, researchers hope to find better treatments for patients battling thyroid cancers.
Results from my study demonstrated that CTX-SAP decreased cell viability of ML-1 cells that
express MMP-2, which points towards MMP-2 as a potential target for RAI-resistant thyroid
cancer. However, further studies are needed to develop safe and effective treatments against
aggressive thyroid cancer using CTX-SAP. Since the discovery of the first platinum-based anticancer drug, Cisplatin, a great deal of research has been conducted in elucidating better
alternative platinum or metal-based anti-cancer drugs. Due to the adverse side effects associated
with treatment, researchers are looking to develop and validate selective metal-based anti-cancer
drugs for cancer therapy. Presently, in vivo studies utilizing healthy mice show great promise in
reducing these chemotherapy-induced side effects (Dannen, Cornelison et al., 2020). However,
challenges still remain and more research needs to be done in an animal cancer model to
determine how intraperitoneal administration affects the entire organism. My study demonstrated
that Pt (DECO)2 has potential for use as an anti-cancer drug. Further studies are needed to
develop safe and effective treatment against aggressive thyroid cancer using this cyanoximate as
an alternative to existing platinum-based anti-cancer drugs. Current research shows promise of Pt
(DECO)2 being more effective than Cisplatin at higher doses. However, more research needs to
be done to test efficacy of both at lower doses and their ability to be used in conjunction with
each other as a combination therapy. Moreover, if the ability to conjugate Pt (DECO)2 to an
MMP-2 receptor agonist like Chlorotoxin would allow for the successful targeting of this drug to
just cancerous cells and not healthy cells too.
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Table 1: American Cancer Society Information & Statistics on Thyroid Cancer
Type of Thyroid
Signs &
Description
Occurrence
Cancer
Symptoms
Papillary (PTC)

Slowly develop in
one lobe of thyroid
gland & spread to
LN. (DTC)

Most common, considered
differentiated

8 out of 10 of all thyroid
cancers

Follicular (FTC)

Rarely spread to LN,
but do spread to other
body parts. (DTC)

Second most common.
More common in iodineinsufficient diets

1 out of 10 of all thyroid
cancers

Medullary (MTC)

Can spread to LN,
lungs, or liver before
nodule present. Alters
blood-calcium levels

4% of all thyroid cancer
cases

Anaplastic (ATC)

Cancer cells do not
resemble normal
thyroid cells (UTC)

Develop in the C cells of
thyroid gland. Can be
familial. Linked to
increased risk of having
other tumors.
Most rare, very aggressive
and difficult to treat, can
metastasize quickly to other
parts of the body.

2% of all thyroid cancers

Source: American Cancer Society: What is Thyroid Cancer?
https://www.cancer.org/cancer/thyroid-cancer/about/what-is-thyroid-cancer.html
DTC – Differentiated Thyroid Cancer

UTC – Undifferentiated Thyroid Cancer

Table 2: National Cancer Institute Treatment Recommendations for Thyroid Cancer
Type of Thyroid Cancer

Disease Status

Treatment Options

Papillary & Follicular

Localized/regional

Surgery (total thyroidectomy or lobectomy), RAI,
TSH, EBRT

Papillary and follicular

Metastatic

Iodine-Sensitive: RAI or Thyroid-suppression therapy
Iodine-resistant:
Thyroid-suppression, targeted therapy, Surgery, or EBRT

Recurrent papillary and
follicular

-

Surgery (W/ or W/o Post-Op RAI), targeted
therapy, EBRT, or Chemotherapy

Medullary

Localized disease

Total thyroidectomy, EBRT

Medullary

Metastatic

Targeted therapy, Palliative Chemotherapy

Anaplastic

-

Surgery, EBRT, Systemic Therapy

Source: National Cancer Institute. Thyroid cancer treatment (PDQ).
www.cancer.gov/cancertopics/pdq/treatment/thyroid/HealthProfessional .

RAI – Radioactive Iodine
TSH – Thyroid Stimulating Hormone
EBRT – External Beam Radiation
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Table 3: Solubility of All Three Platinum Complexes When First Solubilized in 100 µL DMSO
and Diluted with DMEM
Toxins
1% DMSO
2 % DMSO *
4 % DMSO
0 hr.
24 hr.
0 hr.
24 hr.
0 hr.
24 hr.
Pt (DECO)2
Soluble
Soluble
Soluble
Soluble
Soluble Soluble
Pd (DECO)2

Insoluble Insoluble Insoluble Insoluble Soluble Soluble

Cisplatin

Soluble

Soluble

Soluble
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Soluble

Soluble Soluble

Figure 1: Measurement of cellular viability of thyroid cancer cells via reduction of XTT salt.
Data represents absorbance values/relative cell viability (A450-A630) at differing concentrations
(in percentages) of DMSO. A “***” represents p ≤ 0.0001. Results display mean and SD of
triplicate sets.
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Figure 2: Measurement of cellular viability via reduction of XTT. Data represents absorbance
values/ relative cell viability (A450-A630) at differing concentrations of (A) 0 nM – 200 nM
CTX-SAP, (B) 0 nM – 600 nM CTX-SAP, (C), 0 nM – 600 nM CTX, and (D) 0 nM – 600 nM
SAP treatment compared to a non-treated control (NTC). A “*” represents P ≤ 0.05, “**”
represents P ≤ 0.01, and “***” represents p ≤ 0.0001. Results display mean and SD of triplicate
sets.
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Figure 3: Measurement of thyroid cancer cell viability via reduction of XTT salt in ML-1
thyroid cancer cells. Data represents absorbance values/ relative cell viability (A450-A630) at
differing concentrations of Cisplatin and Pt (DECO)2 treatment compared to a non-treated
control (NTC). A “***” represents p ≤ 0.0001. Results display mean and SD of triplicate sets.

Figure 4: Native Gel compared with BIO-RAD protein ladder.
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Figure 5: Quantification of superoxide production in ML-1 thyroid cancer cells using
dihydroethidium (DHE) as standard and analysis at 518/606 nm. “A” shows the fluorescent
intensity of DHE on cells not treated with either drug or DMSO. “B” displays the fluorescent
intensity of DHE on cell treated with 2% DMSO. “C” shows fluorescent intensity of DHE on
cells treated with 1.0 mM Cisplatin. “D” displays fluorescent intensity of DHE on cells treated
with 1.0 mM Pt (DECO)2. “E” shows the total percent of ROS produced by each treatment group
done in triplicate. “F” shows the mean fluorescent intensity of each group. “**” represents P ≤
0.01, and “***” represents p ≤ 0.0001. Results display mean and SD of triplicate sets.
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Figure 6: Percent of cancer cells presenting at a particular stage of programmed cell death under
Annexin V-APC (650nm) and Propidium Iodide (620 nm) after 24 hours of treatment. A-D
represent fluorescent intensity of the dyes on each treatment group. “A & E” displays the percent
of necrotic cells present, “B & F” shows cells presenting signs of late apoptosis, “C & G”
displays the percentage of viable cells, and “D & H” shows cells displaying early apoptosis.
A “*” represents P ≤ 0.05, “**” represents P ≤ 0.01, and “***” represents p ≤ 0.0001. Results
display mean and SD of triplicate sets.
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Figure 7: Percent of Fibroblast cells presenting at a particular stage of programmed cell death
under Annexin V-APC (650nm) and Propidium Iodide (620 nm) after 24 hours of treatment. “A”
displays the percent of necrotic cells present, “B” shows cells presenting signs of late apoptosis,
“C” displays the percentage of viable cells, and “D” shows cells displaying early apoptosis. “**”
represents P ≤ 0.01, and “***” represents p ≤ 0.0001. Results display mean and SD of triplicate
sets.
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Figure 8: Measurement of cellular viability via reduction of XTT. Data represents absorbance
values/relative cell viability of thyroid cancer cells (A450-A630) at differing concentrations of
internally-made CTX-SAP at 0 – 1.2 uM concentrations compared to a non-treated control
(NTC). A “*” represents P ≤ 0.05, and “***” represents p ≤ 0.0001. Results display mean and
SD.
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Figure 9: Measurement of cellular viability of thyroid cancer cells via reduction of XTT salt.
Data represents absorbance values/ relative cell viability (A450-A630) at differing
concentrations of Cisplatin and Pt (DECO)2 solubilized in 10% DMSO compared to a nontreated control (NTC). A “***” represents p ≤ 0.0001. Results display mean and SD.
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APPENDICES
Appendix A. Additional Resources
Appendix A: Comparison of Cyanoximates effects in vitro.
Cyanoximate
Viability Reduced by (%):
Rank
(at 1.0 mM)
HeLa
WiDr
HeLa
WiDr
Cisplatin
55/56
12
4
6
Pt(MCO)2
Pd(MCO)2

42
45

73
81

6
5

5
4

Pt(DECO)2
Pd(DECO)2

60
94

95
98

3
2

3
1

Pt(PyrCO)2

95.2

96.4

1

2

Pd(PyrCO)2

-

-

Mixed results (N/A)

Data from Dannen, Cornelison et al., paper, submitted in January of 2020.
Each drug was solubilized in 1% DMSO.
Appendix B. Online Resources
American Cancer Society. 2019 Treatment of Thyroid Cancer, by Type and Stage. Available
at: www. https://www.cancer.org/cancer/thyroid-cancer/treating/by-stage.html (accessed June
14, 2019).
National Cancer Institute n.d. Cancer Stat Facts: Thyroid Cancer. Available at:
www.https://seer.cancer.gov/statfacts/html/thyro.html (accessed June 13th 2018).
National Institutes of Health (US) 2007 Understanding Cancer. Available at:
www.https://www.ncbi.nlm.nih.gov/books/NBK20362/ (accessed August 8, 2019).
XTT Cell Proliferation Assay Kit: Instruction Manual. 2011. Available at:
https://www.atcc.org/~/media/Attachments/5/6/3/7/16747.ashx (accessed June 13th 2018).
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